Comparable Efficacy and Safety of Brodalumab in Obese and Non-Obese Patients With Psoriasis: Analysis of 2 Randomized Controlled Trials.

CONCLUSIONS: Efficacy and safety of brodalumab did not differ between patients with moderate-to-severe psoriasis who had a BMI <30 kg/m2 and a BMI ≥30 kg/m2 . This article is protected by copyright. All rights reserved. PMID: 31276189 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31276189?dopt=Abstract

Source: The British Journal of Dermatology - July 4, 2019 Category: Dermatology Authors: Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA Tags: Br J Dermatol Source Type: research